Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Περιεχόμενα  Φάρμακα Α - Ζ  Συγχορήγηση

PROSTIN E2 Vaginal tablet (2018)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Prostin E2 Vaginal Tablets 3mg.

Qualitative and quantitative composition

Each tablet contains 3 mg dinoprostone. For the full list of excipients, see section 6.1.

Pharmaceutical form

Vaginal tablet. White, biconvex, oblong tablet, embossed with Upjohn 715 on one side and plain on the other.

Therapeutic indications

Oxytocic agent. Prostin E2 Vaginal Tablets are indicated for the induction of labour, especially in patients with favourable induction features, when there are no foetal or maternal contra-indications. ...

Posology and method of administration

Posology Adults One tablet to be inserted high into the posterior fornix. A second tablet may be inserted after six to eight hours if labour is not established. Maximum dose 6 mg. Elderly Not applicable. ...

Contraindications

Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1. Prostin E2 Vaginal Tablets should not be used where the patient is sensitive to prostaglandins or other constituents ...

Special warnings and precautions for use

This product is only available to hospitals and clinics with specialised obstetric units and should only be used where 24-hour resident medical cover is provided. Use caution in handling this product to ...

Interaction with other medicinal products and other forms of interaction

Since it has been found that prostaglandins potentiate the effect of oxytocin, it is not recommended that these drugs are used together. If used in sequence, the patients uterine activity should be carefully ...

Pregnancy and lactation

Pregnancy Prostin E2 Vaginal Tablets are only used during pregnancy, to induce labour. Breast-feeding Prostaglandins are excreted in breast milk. This is not expected to be a hazard given the circumstances ...

Effects on ability to drive and use machines

Not relevant.

Undesirable effects

Cardiac disorders: Cardiac arrest Vascular disorders: Hypertension Gastrointestinal disorders: Diarrhoea, nausea, vomiting General disorders and administration site conditions: Fever Immune system disorders: ...

Overdose

Overdosage may be expressed by uterine hypercontractility and uterine hypertonus. During use, uterine activity, fetal status and the progression of cervical dilation should be carefully monitored to detect ...

Pharmacodynamic properties

Pharmacotherapeutic group: Prostaglandins ATC-code: G02AD02 Dinoprostone is a prostaglandin of the E series with actions on smooth muscle; the endogenous substance is termed prostaglandin E<sub>2</sub> ...

Pharmacokinetic properties

Following insertion of the tablet, PGE<sub>2</sub> absorption (as measured by the presence of PGE2 metabolites) increases to reach a peak at about 40 minutes. PGE<sub>2</sub> is rapidly metabolised to ...

Preclinical safety data

Animal studies lasting several weeks at high doses have shown that prostaglandins of the E and F series can induce proliferation of bone. Such effects have also been noted in newborn infants who received ...

List of excipients

Lactose Microcrystalline cellulose Colloidal silicon dioxide Maize starch Magnesium stearate

Incompatibilities

Not applicable.

Shelf life

2 years.

Special precautions for storage

Store in a refrigerator at 2-8°C. Where the tablets are packed in a bottle, the tablets should be used within one month of opening the bottle.

Nature and contents of container

Amber glass bottle with screw cap and tac seal. Each bottle contains a desiccant capsule and 4 tablets. Aluminium foil strip of 4 tablets, each box containing 4 or 8 tablets. Not all pack sizes may be ...

Special precautions for disposal and other handling

Wash hands thoroughly with soap and water after administration. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Marketing authorization holder

Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK

Marketing authorization number(s)

PL 00057/1516

Date of first authorization / renewal of the authorization

Date of first authorisation: 15 March 1982 Date of last renewal: 28 October 2004

Date of revision of the text

01/2018

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: